Impact Factor
3.75
Journal Citation Impact
Estimated influence, citation density, publishing volume, and citation integrity from the analytics table.
Citation rate
4.17
738 total citations
h5-index
34
h5 depth signal
Cited share
83.3%
155 of 186
Total citations
738
Citation footprint
Metric signal
4.10
External metric anchor
Self-citation
5.1%
38 self-citations
Citations Trend
Monthly Publications Cadence
Citing Geographic Demographics
United States
371
China
166
United Kingdom
77
Canada
74
Sweden
68
Citing Fields of Research
Musculoskeletal Disorders
658
Immunology
214
Auto-Inflammatory Disorders
170
Hematology
121
Kidney Diseases
59
Publishing Activity & Reach
Volume, recency, access pattern, and citing-community signals from the journal analytics record.
All-time article footprint
932
Articles tracked across the journal lifetime
Indexed publication set
186
155 cited publications
Last 12 months
146
14.6 publications/month
Open access share
100.0%
146 OA publications in the last year
Leading citing country
United States
371 citing publications
Leading citing field
Musculoskeletal Disorders
658 citing publications
Latest tracked publication
5 October 2026
10 recent records available
Coverage & Indexing History
v7n1, 2020-
v1, 2014-
Active Coverage
Research Focus & Classification
Indexed Subjects
Musculoskeletal Disorders
Issuing & Sponsoring Bodies
issuing body
Lupus Foundation of America
Broad Categories
Allergy and Immunology
Rheumatology
Musculoskeletal Disorders
MeSH Descriptors
Lupus Erythematosus, Systemic
Latest Publications
Recent article records with DOI-first linking and condensed abstracts.
01
DOI 10.1136/lupus-2026-002199
Open DOI
Belimumab prevention against organ damage over 8 years and safety up to 13 years: three pooled open-label, long-term extension SLE studies
Objective: Examine long-term glucocorticoid usage, safety and prevention of organ damage in patients with SLE treated with belimumab plus standard therapy (ST). Methods: This post hoc analysis from three global long-term extension (LTE) ...
02
DOI 10.1136/lupus-2026-002287
Open DOI
Diagnostic accuracy of the Arabic composite autonomic symptom score 31 (COMPASS-31) for detecting autonomic neuropathy in SLE: a cross-sectional validation study
Objective: To evaluate the diagnostic accuracy of the Arabic Composite Autonomic Symptom Score-31 (COMPASS-31) for detecting objectively confirmed autonomic neuropathy in patients with SLE. Methods: In this cross-sectional diagnostic acc...
03
DOI 10.1136/lupus-2026-002001
Open DOI
Protein biomarkers of inflammation in women with SLE and their newborn children
Objectives: In utero exposure to maternal anti-Ro/Sjögren’s syndrome antigen A (SSA) and anti-La/Sjögren’s syndrome antigen B (SSB) autoantibodies activates the fetal type I interferon (IFN) system. Women with SLE often carry a broader r...
04
DOI 10.1136/lupus-2026-002217
Open DOI
Interleukin-22 reflects adverse cardiometabolic features in SLE
Introduction: Interleukin-22 (IL-22), a member of the IL-10 cytokine family, primarily targets non-haematopoietic epithelial and stromal cells, contributing to maintenance of epithelial barrier integrity, antimicrobial immunity and tissu...
05
DOI 10.1136/lupus-2026-002044
Open DOI
Seasonal 25-hydroxyvitamin D levels in new childhood-onset SLE: associations with disease activity and peripheral lymphocyte subsets
Objective: This study aimed to compare 25-hydroxyvitamin D (25-(OH)D) levels and peripheral lymphocyte subsets between children with new childhood-onset SLE and healthy controls across different seasons, and to explore the relationships ...
06
DOI 10.1136/lupus-2026-002123
Open DOI
DIA proteomics of FFPE renal biopsies reveals two molecular subtypes of lupus nephritis and identifies APOL1 as candidate biomarker for stratification
Introduction: Lupus nephritis (LN) exhibits substantial clinical and pathological heterogeneity. We aimed to define proteomics-based molecular subtypes of LN and identify candidate biomarkers for subtype discrimination. Methods: We analy...
07
DOI 10.1136/lupus-2026-001979
Open DOI
Navigating the gap: the challenge of applying treat-to-target in routine lupus care—a national perspective
Objective: (1) To explore practice patterns and variability in the management of systemic lupus erythematosus (SLE) in Spain, including the adoption of the treat-to-target (T2T) strategy; (2) to identify key multilevel contextual factors...
08
DOI 10.1136/lupus-2026-002282
Open DOI
The lupus damage index revision program: Results from the item generation and reduction phases
Objective: A data-driven and expert/patient consensus-based project to develop a revised Systemic Lupus International Collaborating Clinics (SLICC)/American College of Rheumatology (ACR) Damage Index (SDI) is under way supported by SLICC...
09
DOI 10.1136/lupus-2026-002138
Open DOI
High disease activity persists in adults with childhood-onset lupus
Objective: Childhood-onset SLE (cSLE) is often described as more severe than adult-onset disease (aSLE) based largely on cross-sectional studies. We examined differences in disease characteristics, medication use and long-term outcomes b...
10
DOI 10.1136/lupus-2026-002130
Open DOI
Role of repeat kidney biopsy after 6 months of treatment in proliferative lupus nephritis
Objective: To characterise histological response following induction therapy in a real-world cohort of patients with proliferative lupus nephritis (LN) undergoing per-protocol repeat kidney biopsy; to assess the concordance between clini...